Form 4: Teva Pharmaceutical Industries: Director Ronit Satch-Fainaro Reports Share Transactions
SEC Form 4
Director Ronit Satch-Fainaro reported the vesting and disposal of restricted share units resulting in the acquisition of ordinary shares of Teva Pharmaceutical Industries.
Summary
- On June 15, 2024, Ronit Satch-Fainaro, a director of Teva Pharmaceutical Industries, reported transactions involving restricted share units and ordinary shares.
- 21,108 restricted share units vested on June 15, 2024, and were subsequently disposed of.
- Upon vesting, these units converted into 21,108 ordinary shares.
- Following these transactions, Satchi-Fainaro directly owns 88,277 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing share transactions, with neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and share ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the director's shareholding.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted. |
| 06/15/2024 | Restricted Share Units vested and were disposed of, converting into ordinary shares. |
| 06/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.